Tuis084990 • KOSDAQ
add
Helixmith Co Ltd
Vorige sluiting
₩2 820,00
Dagwisseling
₩2 770,00 - ₩2 865,00
Jaarwisseling
₩2 115,00 - ₩4 950,00
Markkapitalisasie
129,98 mjd KRW
Gemiddelde volume
191,83 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
KOSDAQ
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (KRW) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 930,47 m | 13,80% |
Bedryfskoste | 3,14 mjd | -48,69% |
Netto inkomste | -1,53 mjd | 71,47% |
Netto winsgrens | -164,30 | 74,93% |
Wins per aandeel | — | — |
EBITDA | -2,32 mjd | 50,15% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (KRW) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 81,43 mjd | -8,21% |
Totale bates | 147,20 mjd | -27,05% |
Totale aanspreeklikheid | 6,70 mjd | -87,42% |
Totale ekwiteit | 140,50 mjd | — |
Uitstaande aandele | 46,05 m | — |
Prys om te bespreek | 0,92 | — |
Opbrengs op bates | -4,83% | — |
Opbrengs op kapitaal | -5,05% | — |
Kontantvloei
Netto kontantverandering
| (KRW) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -1,53 mjd | 71,47% |
Kontant van bedrywe | -1,78 mjd | 69,42% |
Kontant van beleggings | 35,62 mjd | 1 267,16% |
Kontant van finansiering | -118,78 m | 99,41% |
Netto kontantverandering | 34,01 mjd | 217,30% |
Beskikbare kontantvloei | -1,26 mjd | 62,47% |
Meer oor
Helixmith Co. LTD. is a biotechnology company located in Seoul, South Korea with US presence in San Diego. The company has an extensive gene therapy pipeline, including a non-viral plasmid DNA program for neuromuscular and ischemic disease, a CAR-T program targeting several different types of solid tumors, and an AAV vector program targeting neuromuscular diseases. Helixmith’s lead gene is Engensis, currently in phase III diabetic peripheral neuropathy in the US. Engensis is a plasmid DNA designed to simultaneously express two isoforms of hepatocyte growth factor, HGF 728 and HGF 723. In addition to DPN, Engensis is also being studied in diabetic foot ulcers, amyotrophic lateral sclerosis, coronary artery disease, claudication, and Charcot-Marie-Tooth disease. Wikipedia
Gestig
Nov. 1996
Webwerf
Werknemers
33
